Skip to content

Multi-dimensional diagnosis and treatment for neurocritical patients

Establishment of a platform for the multi-dimensional monitoring and treatment of neurocritical diseases

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300079247
Enrollment
Unknown
Registered
2023-12-28
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurocritical disease

Interventions

Case series:NA

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Neurocritical patients admitted to the Neurosurgical Intensive Care Unit : those with acute consciousness disorders (GCS score = 8 points); or severe neurological dysfunction (NIHSS score = 17 points); or evident primary intracranial injuries, characterized by bleeding volume = 30 mL, or midline structural displacement > 5 mm. 2) Age 18-85 years old. 3) Patients or their family members sign an informed consent form. 4) Patients with clinically supported increased intracranial pressure (evidenced by coma, vomiting, and radiological features of intracranial hypertension) may undergo intraventricular intracranial pressure monitoring. This criterion is exempt for patients undergoing solely neuroendocrine function assessment or those suspected of intracranial infection. 5) Patients with clinically supported intracranial infection (evidenced by fever and abnormal cerebrospinal fluid indicators) agree to undergo macro-genomic sequencing of cerebrospinal fluid. This criterion is exempt for patients undergoing solely intracranial pressure/cerebral hemodynamic assessment or neuroendocrine function assessment.

Exclusion criteria

Exclusion criteria: 1) Individuals with severe liver or kidney dysfunction, severe endocrine disorders, heart failure, or severe immunodeficiency. 2) Those with concurrent significant injuries to other vital organs. 3) Anticipated life expectancy less than 1 month. 4) Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
blood pressure;Cerebral blood perfusion;perihematomal edema volume;mRS;rate of CNS infection;

Secondary

MeasureTime frame
length of intensive care;length of Mechanical ventilation;medical cost;

Countries

China

Contacts

Public ContactJunji Wei

Peking Union Medical College Hospital

weijunji@pumch.cn+86 158 0105 6698

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026